Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells

Immunity

Volumn 45, Issue 5, 2016, Pages 1135-1147

  De Simone, Marco ^a   Arrigoni, Alberto ^a   Rossetti, Grazisa ^a   Gruarin, Paola ^a   Ranzani, Valeria ^a   Politano, Claudia ^a   Bonnal, Raoul J P ^a   Provasi, Elena ^a   Sarnicola, Maria Lucia ^a   Panzeri, Ilaria ^a   Moro, Monica ^a   Crosti, Mariacristina ^a   Mazzara, Saveria ^a   Vaira, Valentina ^a,b,c   Bosari, Silvano ^b,c   Palleschi, Alessandro ^b   Santambrogio, Luigi ^b,c   Bovo, Giorgio ^d   Zucchini, Nicola ^d   Totis, Mauro ^d   Gianotti, Luca ^d,e   Cesana, Giancarlo ^e   Perego, Roberto A ^e   Maroni, Nirvana ^f   Pisani Ceretti, Andrea ^f   Opocher, Enrico ^c,f   De Francesco, Raffaele ^a   Geginat, Jens ^a   Stunnenberg, Hendrik G ^g   Abrignani, Sergio ^a,c   Pagani, Massimiliano ^a,c   more..

^a Istituto Nazionale di Genetica Molecolare   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f SAN PAOLO HOSPITAL   (Italy)

^g RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD134 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR8; COMPLEMENTARY DNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; LAYN PROTEIN; MAGEH1 PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; TRANSCRIPTION FACTOR NFAT5; UNCLASSIFIED DRUG; TRANSCRIPTOME;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; AGED; CELL SEPARATION; COLORECTAL TUMOR; FEMALE; GENE EXPRESSION PROFILING; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; POLYMERASE CHAIN REACTION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL SEPARATION; COLORECTAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTOME;

EID: 84999673353     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.10.021     Document Type: Article

References (56)

1. Arpaia, N., Green, J.A., Moltedo, B., Arvey, A., Hemmers, S., Yuan, S., Treuting, P.M., Rudensky, A.Y., A Distinct Function of Regulatory T Cells in Tissue Protection. Cell 162 (2015), 1078–1089.
2. Bindea, G., Galon, J., Mlecnik, B., CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics 29 (2013), 661–663.
3. Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A.C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39 (2013), 782–795.
4. Borowsky, M.L., Hynes, R.O., Layilin, a novel talin-binding transmembrane protein homologous with C-type lectins, is localized in membrane ruffles. J. Cell Biol. 143 (1998), 429–442.
5. Boussiotis, V.A., Chatterjee, P., Li, L., Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J. 20 (2014), 265–271.
6. Burzyn, D., Kuswanto, W., Kolodin, D., Shadrach, J.L., Cerletti, M., Jang, Y., Sefik, E., Tan, T.G., Wagers, A.J., Benoist, C., Mathis, D., A special population of regulatory T cells potentiates muscle repair. Cell 155 (2013), 1282–1295.
7. Campbell, D.J., Koch, M.A., Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat. Rev. Immunol. 11 (2011), 119–130.
8. Carthon, B.C., Wolchok, J.D., Yuan, J., Kamat, A., Ng Tang, D.S., Sun, J., Ku, G., Troncoso, P., Logothetis, C.J., Allison, J.P., Sharma, P., Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16 (2010), 2861–2871.
9. Chen, J., Yao, Y., Gong, C., Yu, F., Su, S., Chen, J., Liu, B., Deng, H., Wang, F., Lin, L., et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19 (2011), 541–555.
10. Cipolletta, D., Feuerer, M., Li, A., Kamei, N., Lee, J., Shoelson, S.E., Benoist, C., Mathis, D., PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486 (2012), 549–553.
11. Duhen, T., Duhen, R., Lanzavecchia, A., Sallusto, F., Campbell, D.J., Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 119 (2012), 4430–4440.
12. Fridman, W.H., Pagès, F., Sautès-Fridman, C., Galon, J., The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12 (2012), 298–306.
13. Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., Kroemer, G., Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell 28 (2015), 690–714.
14. Geginat, J., Paroni, M., Maglie, S., Alfen, J.S., Kastirr, I., Gruarin, P., De Simone, M., Pagani, M., Abrignani, S., Plasticity of human CD4 T cell subsets. Front. Immunol., 5, 2014, 630.
15. Gentles, A.J., Newman, A.M., Liu, C.L., Bratman, S.V., Feng, W., Kim, D., Nair, V.S., Xu, Y., Khuong, A., Hoang, C.D., et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21 (2015), 938–945.
16. Gonzalez-Pons, M., Cruz-Correa, M., Colorectal Cancer Biomarkers: Where Are We Now?. BioMed Res. Int., 2015, 2015, 149014.
17. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
18. Islam, S.A., Ling, M.F., Leung, J., Shreffler, W.G., Luster, A.D., Identification of human CCR8 as a CCL18 receptor. J. Exp. Med. 210 (2013), 1889–1898.
19. Jacobs, J., Smits, E., Lardon, F., Pauwels, P., Deschoolmeester, V., Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J. Immunol. Res., 2015, 2015, 158038.
20. Jamal-Hanjani, M., Thanopoulou, E., Peggs, K.S., Quezada, S.A., Swanton, C., Tumour heterogeneity and immune-modulation. Curr. Opin. Pharmacol. 13 (2013), 497–503.
21. Joller, N., Lozano, E., Burkett, P.R., Patel, B., Xiao, S., Zhu, C., Xia, J., Tan, T.G., Sefik, E., Yajnik, V., et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40 (2014), 569–581.
22. Josefowicz, S.Z., Lu, L.F., Rudensky, A.Y., Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30 (2012), 531–564.
23. Kharchenko, P.V., Silberstein, L., Scadden, D.T., Bayesian approach to single-cell differential expression analysis. Nat. Methods 11 (2014), 740–742.
24. Kroemer, G., Galluzzi, L., Zitvogel, L., Fridman, W.H., Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. OncoImmunology, 4, 2015, e1058597.
25. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
26. Lesterhuis, W.J., Steer, H., Lake, R.A., PD-L2 is predominantly expressed by Th2 cells. Mol. Immunol. 49 (2011), 1–3.
27. Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R.C., Zhou, G., Rajapaksa, R., Green, M.R., Torchia, J., Brody, J., et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. 123 (2013), 2447–2463.
28. Messal, N., Serriari, N.E., Pastor, S., Nunès, J.A., Olive, D., PD-L2 is expressed on activated human T cells and regulates their function. Mol. Immunol. 48 (2011), 2214–2219.
29. Munn, D.H., Bronte, V., Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 39 (2016), 1–6.
30. Murphy, T.L., Tussiwand, R., Murphy, K.M., Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat. Rev. Immunol. 13 (2013), 499–509.
31. Nishikawa, H., Sakaguchi, S., Regulatory T cells in tumor immunity. Int. J. Cancer 127 (2010), 759–767.
32. Panduro, M., Benoist, C., Mathis, D., Tissue Tregs. Annu. Rev. Immunol. 34 (2016), 609–633.
33. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
34. Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J., Allison, J.P., Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206 (2009), 1717–1725.
35. Ranzani, V., Rossetti, G., Panzeri, I., Arrigoni, A., Bonnal, R.J., Curti, S., Gruarin, P., Provasi, E., Sugliano, E., Marconi, M., et al. The long intergenic noncoding RNA landscape of human lymphocytes highlights the regulation of T cell differentiation by linc-MAF-4. Nat. Immunol. 16 (2015), 318–325.
36. Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M., Regulatory T cells and immune tolerance. Cell 133 (2008), 775–787.
37. Sato, M., Larsen, J.E., Lee, W., Sun, H., Shames, D.S., Dalvi, M.P., Ramirez, R.D., Tang, H., DiMaio, J.M., Gao, B., et al. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol. Cancer Res. 11 (2013), 638–650.
38. Schoenbrunn, A., Frentsch, M., Kohler, S., Keye, J., Dooms, H., Moewes, B., Dong, J., Loddenkemper, C., Sieper, J., Wu, P., et al. A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg. J. Immunol. 189 (2012), 5985–5994.
39. Schutyser, E., Richmond, A., Van Damme, J., Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J. Leukoc. Biol. 78 (2005), 14–26.
40. Selby, M.J., Engelhardt, J.J., Quigley, M., Henning, K.A., Chen, T., Srinivasan, M., Korman, A.J., Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1 (2013), 32–42.
41. Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161 (2015), 205–214.
42. Simpson, T.R., Li, F., Montalvo-Ortiz, W., Sepulveda, M.A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J.Y., Yagita, H., Wolchok, J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210 (2013), 1695–1710.
43. Śledzińska, A., Menger, L., Bergerhoff, K., Peggs, K.S., Quezada, S.A., Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol. Oncol. 9 (2015), 1936–1965.
44. Smith, J.J., Deane, N.G., Wu, F., Merchant, N.B., Zhang, B., Jiang, A., Lu, P., Johnson, J.C., Schmidt, C., Bailey, C.E., et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 138 (2010), 958–968.
45. Teng, M.W., Ngiow, S.F., von Scheidt, B., McLaughlin, N., Sparwasser, T., Smyth, M.J., Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res. 70 (2010), 7800–7809.
46. Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
47. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J. Clin. 65 (2015), 87–108.
48. Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., Benci, J.L., Xu, B., Dada, H., Odorizzi, P.M., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
49. van den Eertwegh, A.J., Versluis, J., van den Berg, H.P., Santegoets, S.J., van Moorselaar, R.J., van der Sluis, T.M., Gall, H.E., Harding, T.C., Jooss, K., Lowy, I., et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13 (2012), 509–517.
50. Voo, K.S., Bover, L., Harline, M.L., Vien, L.T., Facchinetti, V., Arima, K., Kwak, L.W., Liu, Y.J., Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J. Immunol. 191 (2013), 3641–3650.
51. Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.Y., Mendrzyk, R., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18 (2012), 1254–1261.
52. Weon, J.L., Potts, P.R., The MAGE protein family and cancer. Curr. Opin. Cell Biol. 37 (2015), 1–8.
53. Wirth, H., von Bergen, M., Binder, H., Mining SOM expression portraits: feature selection and integrating concepts of molecular function. BioData Min., 5, 2012, 18.
54. Xin, G., Schauder, D.M., Lainez, B., Weinstein, J.S., Dai, Z., Chen, Y., Esplugues, E., Wen, R., Wang, D., Parish, I.A., et al. A Critical Role of IL-21-Induced BATF in Sustaining CD8-T-Cell-Mediated Chronic Viral Control. Cell Rep. 13 (2015), 1118–1124.
55. Yang, J.C., Hughes, M., Kammula, U., Royal, R., Sherry, R.M., Topalian, S.L., Suri, K.B., Levy, C., Allen, T., Mavroukakis, S., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30 (2007), 825–830.
56. Zitvogel, L., Galluzzi, L., Smyth, M.J., Kroemer, G., Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39 (2013), 74–88.